Primary OS analysis results from STELLAR-303 showed zanzalintinib + atezolizumab improved OS vs regorafenib in metastatic colorectal cancer.

The percentage of those with early-onset diverticulitis admitted for complicated diverticulitis went from 18.5% to 28.2% from 2005 to 2020.

Developers of biosimilars will no longer be required to conduct clinical trials to prove effectiveness for FDA approval.

Physicians with H-1B-sponsored visas accounted for 0.97% of physicians in the United States in fiscal year 2024.

Nearly two-thirds of asymptomatic adults in a US safety-net health care system tested positive for Helicobacter pylori antibodies.